Evidence map›Paper›PMID 38077723›Full record

ArticlePublic health action2023

Descriptors of multidrug-resistant TB deaths in Ethiopia.

E Tesema, Z G Dememew, D G Datiko, A Gebreyohannes, Y Molla, A Tefera, G Gizatie, T Bogale, M Million, P G Suarez and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Public health action, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

E TesemaUnited States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.
Z G DememewUSAID Eliminate TB Project, MSH, Addis Ababa, Ethiopia.
D G DatikoUSAID Eliminate TB Project, MSH, Addis Ababa, Ethiopia.
A GebreyohannesUnited States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.
Y MollaUSAID Eliminate TB Project, MSH, Addis Ababa, Ethiopia.
A TeferaUnited States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.
G GizatieUnited States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.
T BogaleUnited States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.
M MillionUnited States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.
P G SuarezManagement Sciences for Health, Global Health Systems Innovation, Arlington, VA, USA.
M M AseressaManagement Sciences for Health, Global Health Systems Innovation, Arlington, VA, USA.
D JereneKNCV Tuberculosis Foundation, The Hague, The Netherlands.
M BiruUnited States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia.
United States Agency for International Development · USInternational Trachoma Initiative · ETManagement Sciences for Health · USTuBerculosis Vaccine Initiative · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deaths related to multidrug-resistant TB among patients who had received a second-line anti-TB drugs in Ethiopia were analysed. Respectively 38/704 (5.4%) and 44/995 (4.4%) deaths were identified in two cohorts (2015 and 2022). In the 2015 cohort, severe malnutrition was less prevalent, previous treatment rates were three times higher, hypokalaemia was more frequent, and the use of the Xpert® MTB/RIF assay, respiratory failure and severe anaemia/pancytopenia were less common than in the 2022 cohort. We observed that there were variations in adverse events when different treatment regimens were used over different time periods. To ensure proper patient care, correct guidance must be consistently implemented.

Indexed as

drug-resistant TB deathsEthiopiarifampicin-resistant TBRR/MDR-TBTB-related mortality

Identifiers

PMID38077723
PMCPMC10703136
OpenAlexW4389484248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.